An Open-Label, Expanded Access Protocol of Iniparib in Combination With Gemcitabine/Carboplatin in Patients With ER-, PR-, and HER2-Negative Metastatic Breast Cancer.

Trial Profile

An Open-Label, Expanded Access Protocol of Iniparib in Combination With Gemcitabine/Carboplatin in Patients With ER-, PR-, and HER2-Negative Metastatic Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2012

At a glance

  • Drugs Carboplatin; Gemcitabine; Iniparib
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Apr 2011 Additional lead trial investigator (Specht Jennifer) identified as reported by University of Washington Health Sciences.
    • 26 Apr 2011 New source identified and integrated (University of Washington Health Sciences; 1009).
    • 31 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top